These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31312412)

  • 1. Targeting IRAK4 for Degradation with PROTACs.
    Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA
    ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
    Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
    Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.
    Chen Y; Ning Y; Bai G; Tong L; Zhang T; Zhou J; Zhang H; Xie H; Ding J; Duan W
    ACS Med Chem Lett; 2021 Jan; 12(1):82-87. PubMed ID: 33488968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-27a Negatively Modulates the Inflammatory Response in Lipopolysaccharide-Stimulated Microglia by Targeting TLR4 and IRAK4.
    Lv YN; Ou-Yang AJ; Fu LS
    Cell Mol Neurobiol; 2017 Mar; 37(2):195-210. PubMed ID: 26971344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production.
    Valaperti A; Nishii M; Liu Y; Naito K; Chan M; Zhang L; Skurk C; Schultheiss HP; Wells GA; Eriksson U; Liu PP
    Circulation; 2013 Oct; 128(14):1542-54. PubMed ID: 24030499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical role for IRAK4 kinase activity in Toll-like receptor-mediated innate immunity.
    Kim TW; Staschke K; Bulek K; Yao J; Peters K; Oh KH; Vandenburg Y; Xiao H; Qian W; Hamilton T; Min B; Sen G; Gilmour R; Li X
    J Exp Med; 2007 May; 204(5):1025-36. PubMed ID: 17470642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRAK4 activity controls immune responses to intracellular bacteria Listeria monocytogenes and Mycobacterium smegmatis.
    Pattabiraman G; Murphy M; Agliano F; Karlinsey K; Medvedev AE
    J Leukoc Biol; 2018 Oct; 104(4):811-820. PubMed ID: 29749650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
    Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
    Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation.
    Rekhter M; Staschke K; Estridge T; Rutherford P; Jackson N; Gifford-Moore D; Foxworthy P; Reidy C; Huang XD; Kalbfleisch M; Hui K; Kuo MS; Gilmour R; Vlahos CJ
    Biochem Biophys Res Commun; 2008 Mar; 367(3):642-8. PubMed ID: 18190779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Potent Benzolactam IRAK4 Inhibitors with Robust in Vivo Activity.
    Rajapaksa NS; Gobbi A; Drobnick J; Do S; Kolesnikov A; Liang J; Chen Y; Sujatha-Bhaskar S; Huang Z; Brightbill H; Francis R; Yu C; Choo EF; DeMent K; Ran Y; An L; Emson C; Maher J; Wai J; McKenzie BS; Lupardus PJ; Zarrin AA; Kiefer JR; Bryan MC
    ACS Med Chem Lett; 2020 Mar; 11(3):327-333. PubMed ID: 32184965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
    Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
    Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
    Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
    SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid.
    Park SH; Baek SI; Yun J; Lee S; Yoon DY; Jung JK; Jung SH; Hwang BY; Hong JT; Han SB; Kim Y
    J Immunol; 2015 Feb; 194(3):1122-30. PubMed ID: 25548221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
    Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
    Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-1β-induced interleukin-6 production in A549 cells is mediated by both phosphatidylinositol 3-kinase and interleukin-1 receptor-associated kinase-4.
    Eda H; Burnette BL; Shimada H; Hope HR; Monahan JB
    Cell Biol Int; 2011 Apr; 35(4):355-8. PubMed ID: 21166654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.